Nycrist Technology Co.,Ltd was established in 2015, headquartered in Guangming District, Shenzhen, with a registered capital of RMB 47.596 million. As the first domestic company to apply Raman spectroscopy technology in reverse analyzing various complex formulations, Nycrist focuses on in-depth investigation in solid state and formulation development, from lab scale to commercialization. With the core mission of solving the most challenging solid state problems during the complex formulation development.
With high-standard service system and profound solid state research technology, we are capable of optimizing R&D efficiency, managing R&D risks, accelerating the drug development process, and eventually facilitating product advancement to the market.
Nycrist's manufacturing plant is an integrated platform for various novel solid state dosage forms, including three main production lines of topical products, oral film, tablets and capsules.
